drug prices — Patient associations in Cyprus have expressed their concern over rising drug prices, calling for immediate dialogue regarding recent changes in drug categorisation. This move has led to significant complaints from both patients and healthcare professionals, particularly impacting the elderly population.
Drug prices: Concerns Over Drug Classification Changes
The Federation of Patient Associations (Osak) has initiated discussions with the Health Insurance Organisation (HIO) to address the financial burden placed on patients due to the reclassification of certain drugs within the national health system, known as Gesy. Osak is closely monitoring the repercussions of these changes, which stem from the expiration of patents on several original medications.
Financial Implications for Patients
As a result of the reclassification, many patients are now facing higher out-of-pocket expenses despite no change in the actual medication prices. “The contribution demanded from the patient has risen, without the price of the actual drug having changed,” Osak noted. This situation has prompted an influx of complaints from patients and doctors alike, highlighting the challenges posed by these new financial obligations.
Impact on Vulnerable Populations
The reclassification issue is particularly detrimental to elderly patients, especially those who are pensioners or on low incomes. Many are forced to pay significantly more each month for their treatments, in some cases for a single medication. The federation has emphasised that patients should not bear the financial brunt of expired patents and price fluctuations.
Call for Collaborative Solutions
Osak has urged pharmaceutical companies to join the discussions in order to find a collaborative solution to this pressing issue. The federation believes that the selection of medications should not be dictated by changes in patient contributions arising from these reclassifications. They are advocating for a system that protects patients from undue financial strain while ensuring access to necessary treatments.
Looking Ahead
As discussions continue, the Federation of Patient Associations remains committed to advocating for the rights of patients affected by these changes. The hope is that a resolution can be reached that alleviates the financial pressure on those who need it most.
